Viatris (NASDAQ: VTRS) spun off from Pfizer and merged with Mylan back in 2020. It's a generic drugmaker with a diverse, global business that serves patients and customers in over 165 countries and territories. It has approximately 40 manufacturing facilities, which help it manufacture drugs that serve many therapeutic areas. That diversity should make this a fairly stable investment to hang on to.

However, you may be surprised at what your returns would have been if you bought and held shares of Viatris since it first came into existence.

Viatris officially launched on Nov. 16, 2020. The following day it began trading under the ticker symbol VTRS. More than 60 million shares traded that day, with the stock price ranging between $15.30 and $17.93, closing at $16.34. If you'd invested $25,000 back then, you would have been able to acquire approximately 1,530 shares of the business -- assuming you bought the stock at around the closing price.

Continue reading

Source Fool.com